Last reviewed · How we verify
Intravitreal injections of ziv-aflibercept
Intravitreal injections of ziv-aflibercept is a Small molecule drug developed by Retina Clinic, Sao Paulo, Brazil. It is currently in Phase 1 development. Also known as: Intravitreal injections of Zaltrap.
At a glance
| Generic name | Intravitreal injections of ziv-aflibercept |
|---|---|
| Also known as | Intravitreal injections of Zaltrap |
| Sponsor | Retina Clinic, Sao Paulo, Brazil |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (PHASE3)
- High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes (PHASE4)
- Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL (NA)
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (PHASE3)
- A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
- Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal injections of ziv-aflibercept CI brief — competitive landscape report
- Intravitreal injections of ziv-aflibercept updates RSS · CI watch RSS
- Retina Clinic, Sao Paulo, Brazil portfolio CI
Frequently asked questions about Intravitreal injections of ziv-aflibercept
What is Intravitreal injections of ziv-aflibercept?
Intravitreal injections of ziv-aflibercept is a Small molecule drug developed by Retina Clinic, Sao Paulo, Brazil.
Who makes Intravitreal injections of ziv-aflibercept?
Intravitreal injections of ziv-aflibercept is developed by Retina Clinic, Sao Paulo, Brazil (see full Retina Clinic, Sao Paulo, Brazil pipeline at /company/retina-clinic-sao-paulo-brazil).
Is Intravitreal injections of ziv-aflibercept also known as anything else?
Intravitreal injections of ziv-aflibercept is also known as Intravitreal injections of Zaltrap.
What development phase is Intravitreal injections of ziv-aflibercept in?
Intravitreal injections of ziv-aflibercept is in Phase 1.
Related
- Manufacturer: Retina Clinic, Sao Paulo, Brazil — full pipeline
- Also known as: Intravitreal injections of Zaltrap